Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Colorcon
McKesson
Healthtrust
Harvard Business School
Covington
Baxter
Cantor Fitzgerald

Generated: January 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202514

« Back to Dashboard

NDA 202514 describes ZIOPTAN, which is a drug marketed by Oak Pharms Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ZIOPTAN profile page.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tafluprost profile page.
Summary for 202514
Tradename:ZIOPTAN
Applicant:Oak Pharms Inc
Ingredient:tafluprost
Patents:2
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 202514
Generic Entry Date for 202514*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 202514
Suppliers and Packaging for NDA: 202514
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514 NDA Akorn, Inc. 17478-609 17478-609-10 1 POUCH in 1 CARTON (17478-609-10) > 10 VIAL, SINGLE-USE in 1 POUCH (17478-609-01) > .3 mL in 1 VIAL, SINGLE-USE
ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514 NDA Akorn, Inc. 17478-609 17478-609-30 3 POUCH in 1 CARTON (17478-609-30) > 10 VIAL, SINGLE-USE in 1 POUCH (17478-609-01) > .3 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.0015%
Approval Date:Feb 10, 2012TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Dec 18, 2022Product Flag?YSubstance Flag?YDelist Request?
Patented Use:REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Patent:➤ Sign UpPatent Expiration:May 28, 2029Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Express Scripts
Colorcon
Johnson and Johnson
Fuji
McKesson
Baxter
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.